• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于心脏淀粉样变性亚分类的血清游离轻链分析的优化

Optimization of Serum Immunoglobulin Free Light Chain Analysis for Subclassification of Cardiac Amyloidosis.

作者信息

Halushka Marc K, Eng George, Collins A Bernard, Judge Daniel P, Semigran Marc J, Stone James R

机构信息

Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

出版信息

J Cardiovasc Transl Res. 2015 Jun;8(4):264-8. doi: 10.1007/s12265-015-9628-2. Epub 2015 Apr 30.

DOI:10.1007/s12265-015-9628-2
PMID:25925232
Abstract

Accurate and rapid classification of cardiac amyloidosis is important for patient management. We have optimized the use of serum free light chain kappa and lambda values to differentiate immunoglobulin light chain amyloid (AL) amyloidosis from transthyretin amyloid and amyloid A using 85 cases of tissue-proven cardiac amyloidosis, in which there was direct classification of amyloidosis by mass spectrometry or immunofluorescence. The serum free light chain kappa/lambda ratios were non-overlapping for the three major groups: AL-lambda (0.01-0.41, n = 30), non-AL (0.52-2.7, n = 43), and AL-kappa (6.7-967, n = 12). A kappa/lambda ratio value between 0.5 and 5.0 had 100 % sensitivity and 100 % specificity for distinguishing AL amyloidosis from non-AL amyloidosis. This optimized range for serum light chain kappa/lambda ratio provides extremely robust classification of cardiac amyloidosis. Cases of cardiac amyloidosis in which the serum kappa/lambda free light chain ratio falls close to these new cutoff values may benefit most from direct amyloid subtyping.

摘要

准确快速地对心脏淀粉样变性进行分类对于患者管理至关重要。我们利用85例经组织证实的心脏淀粉样变性病例,优化了血清游离轻链κ和λ值的应用,以区分免疫球蛋白轻链淀粉样变性(AL)与转甲状腺素蛋白淀粉样变性和淀粉样蛋白A,其中通过质谱或免疫荧光对淀粉样变性进行了直接分类。血清游离轻链κ/λ比值在三个主要组中不重叠:AL-λ(0.01 - 0.41,n = 30)、非AL(0.52 - 2.7,n = 43)和AL-κ(6.7 - 967,n = 12)。κ/λ比值在0.5至5.0之间对区分AL淀粉样变性与非AL淀粉样变性具有100%的敏感性和100%的特异性。血清轻链κ/λ比值的这一优化范围为心脏淀粉样变性提供了极为可靠的分类。血清κ/λ游离轻链比值接近这些新临界值的心脏淀粉样变性病例可能最受益于直接淀粉样变性亚型分类。

相似文献

1
Optimization of Serum Immunoglobulin Free Light Chain Analysis for Subclassification of Cardiac Amyloidosis.用于心脏淀粉样变性亚分类的血清游离轻链分析的优化
J Cardiovasc Transl Res. 2015 Jun;8(4):264-8. doi: 10.1007/s12265-015-9628-2. Epub 2015 Apr 30.
2
Strong transthyretin immunostaining: potential pitfall in cardiac amyloid typing.强转甲状腺素蛋白免疫染色:心脏淀粉样变性分型的潜在陷阱。
Am J Surg Pathol. 2011 Nov;35(11):1685-90. doi: 10.1097/PAS.0b013e3182263d74.
3
[The prognostic value of baseline serum free light chain in cardiac amyloidosis].[基线血清游离轻链在心脏淀粉样变性中的预后价值]
Zhonghua Nei Ke Za Zhi. 2016 Mar;55(3):186-90. doi: 10.3760/cma.j.issn.0578-1426.2016.03.006.
4
A patient with AL amyloidosis with negative free light chain results.一位有 AL 淀粉样变性且游离轻链检测结果为阴性的患者。
Clin Chem Lab Med. 2016 Jun 1;54(6):1035-7. doi: 10.1515/cclm-2015-0847.
5
Diagnostic approach to and follow-up of difficult cases of AL amyloidosis.AL淀粉样变性疑难病例的诊断方法及随访
Haematologica. 1995 Sep-Oct;80(5):409-15.
6
Pathological review of cardiac amyloidosis using autopsy cases in a single Japanese institution.日本单家机构尸检病例中心血管淀粉样变性的病理分析。
Pathol Res Pract. 2021 Nov;227:153635. doi: 10.1016/j.prp.2021.153635. Epub 2021 Sep 28.
7
Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosis.血清游离轻链定量检测在AL淀粉样变性诊断评估中的应用
Amyloid. 2005 Dec;12(4):210-5. doi: 10.1080/13506120500352339.
8
[Classification of cardiac amyloidosis: an immunohistochemical analysis].[心脏淀粉样变性的分类:免疫组织化学分析]
Zhonghua Bing Li Xue Za Zhi. 2018 Feb 8;47(2):105-109. doi: 10.3760/cma.j.issn.0529-5807.2018.02.005.
9
Prevalence of Monoclonal Gammopathy in Wild-Type Transthyretin Amyloidosis.野生型转甲状腺素蛋白淀粉样变性中单克隆丙种球蛋白病的患病率。
Mayo Clin Proc. 2017 Dec;92(12):1800-1805. doi: 10.1016/j.mayocp.2017.09.016.
10
Amyloidomas of the nervous system: a monoclonal B-cell disorder with monotypic amyloid light chain lambda amyloid production.神经系统淀粉样瘤:一种产生单型淀粉样轻链λ的单克隆B细胞疾病。
Cancer. 1998 Jan 15;82(2):362-74. doi: 10.1002/(sici)1097-0142(19980115)82:2<375::aid-cncr18>3.0.co;2-w.

引用本文的文献

1
The Influence of Deterioration of Kidney Function on the Diagnostic Power of Laboratory Parameters Used in the Prognostic Classification of AL Amyloidosis.肾功能恶化对用于AL淀粉样变性预后分类的实验室参数诊断效能的影响。
J Clin Med. 2021 Oct 24;10(21):4903. doi: 10.3390/jcm10214903.
2
Clinical Phenotyping of Transthyretin Cardiac Amyloidosis with Bone-Seeking Radiotracers in Heart Failure with Preserved Ejection Fraction.心力衰竭伴射血分数保留患者中应用亲骨性放射性示踪剂对转甲状腺素蛋白心脏淀粉样变进行临床表型分析。
Curr Cardiol Rep. 2018 Mar 8;20(4):23. doi: 10.1007/s11886-018-0970-2.
3
Serum Amyloid P-Component Prevents Cardiac Remodeling in Hypertensive Heart Disease.

本文引用的文献

1
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.国际骨髓瘤工作组更新了多发性骨髓瘤的诊断标准。
Lancet Oncol. 2014 Nov;15(12):e538-48. doi: 10.1016/S1470-2045(14)70442-5. Epub 2014 Oct 26.
2
Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis.塔法米迪司对非 Val30Met 转甲状腺素蛋白淀粉样变性患者转甲状腺素蛋白稳定性和临床结局的影响。
J Cardiovasc Transl Res. 2013 Dec;6(6):1011-20. doi: 10.1007/s12265-013-9512-x. Epub 2013 Oct 8.
3
Safety and efficacy of RNAi therapy for transthyretin amyloidosis.
血清淀粉样蛋白P成分可预防高血压性心脏病中的心脏重塑。
J Cardiovasc Transl Res. 2015 Dec;8(9):554-66. doi: 10.1007/s12265-015-9661-1. Epub 2015 Nov 17.
RNAi 疗法治疗转甲状腺素淀粉样变性的安全性和有效性。
N Engl J Med. 2013 Aug 29;369(9):819-29. doi: 10.1056/NEJMoa1208760.
4
(99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses.(99m)Tc-焦磷酸盐闪烁显像术鉴别轻链型心脏淀粉样变性与转甲状腺素蛋白相关家族性和老年性心脏淀粉样变性。
Circ Cardiovasc Imaging. 2013 Mar 1;6(2):195-201. doi: 10.1161/CIRCIMAGING.112.000132. Epub 2013 Feb 11.
5
Relationship between monoclonal gammopathy and cardiac amyloid type.单克隆丙种球蛋白血症与心脏淀粉样变性的关系。
Cardiovasc Pathol. 2013 May-Jun;22(3):189-94. doi: 10.1016/j.carpath.2012.09.001. Epub 2012 Oct 24.
6
Transthyretin (TTR) cardiac amyloidosis.转甲状腺素蛋白(TTR)心脏淀粉样变性
Circulation. 2012 Sep 4;126(10):1286-300. doi: 10.1161/CIRCULATIONAHA.111.078915.
7
2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology.2011 年欧洲心血管病理学协会和心血管病理学学会关于心内膜心肌活检的共识声明。
Cardiovasc Pathol. 2012 Jul-Aug;21(4):245-74. doi: 10.1016/j.carpath.2011.10.001. Epub 2011 Dec 3.
8
Recommendations for processing cardiovascular surgical pathology specimens: a consensus statement from the Standards and Definitions Committee of the Society for Cardiovascular Pathology and the Association for European Cardiovascular Pathology.心血管外科病理学标本处理建议:心血管病理学学会标准和定义委员会和欧洲心血管病理学协会的共识声明。
Cardiovasc Pathol. 2012 Jan-Feb;21(1):2-16. doi: 10.1016/j.carpath.2011.01.001. Epub 2011 Feb 24.
9
Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure.心脏移植后继以剂量密集美法仑和自体干细胞移植治疗轻链淀粉样变性和心力衰竭。
Transplantation. 2010 Oct 27;90(8):905-11. doi: 10.1097/TP.0b013e3181f10edb.
10
Genetic evaluation of familial cardiomyopathy.家族性心肌病的遗传学评估。
J Cardiovasc Transl Res. 2008 Jun;1(2):144-54. doi: 10.1007/s12265-008-9025-1. Epub 2008 Apr 22.